Drug Discovery pp 133-141 | Cite as


  • Robert A. Maxwell
  • Shohreh B. Eckhardt


Depression has been defined as “a sinking of spirits [affect] so as to constitute a clinically discernible condition” (Stedman, 1982). In earlier times, it was called melancholia. It comprises two major types: (1) severe depression of mood associated with psychomotor retardation or agitation, self-reproach or guilt, as well as other symptoms, all of which occur in the apparent absence of a precipitating cause; (2) severe depression of mood associated directly with an intensely sad external situation, which is relieved by removal of the external situation. The former is referred to as endogenous depression and the latter as reactive depression.


Eating Disorder Reactive Depression Endogenous Depression Tricyclic Agent Close Structural Analog 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baldessarini, R. J.: Biomedical Aspects of Depression and its Treatment, American Psychiatric Press, Washington, DC, 1983.Google Scholar
  2. Baldessarini, R. J.: Drugs and the treatment of psychiatric disorders, in The Pharmacologie Basis of Therapeutics, 7th Ed., A. G. Gilman, L. S. Goodman, T. W. Rail, F. Murad, eds., pp. 387–445, Macmillan, New York, 1985.Google Scholar
  3. Charpentier, P.: Sur la constitution d’une dimethylamino-propyl-N-phéno-thiazine. Comptes Rendus 225:306–308, 1947.Google Scholar
  4. Charpentier, P., Gaillot, P., Jacob, R., Gaudechon, J., and Buisson, P.: Chimie organique—Recherches sur les dimethylaminopropyl-N-phenothiazines substitutuee. Comptes Rendus 235, 59,60,1952.Google Scholar
  5. Delay, J., Deniker, P., and Harl, J. M.: Utilisation en thérapeutique psychiatrique d’une phenothiazine d’action central elective (4560 R.P.) Ann. Méd.-Psychol. (Paris) 110:112–117, 1952a.Google Scholar
  6. Delay, J., Deniker, P., and Harl, J. M.: Traitement des etats d’excitation et d’agitation par une méthode medicamenteuse d’erivee de l’hiberno-therapie. Ann. Méd.-Psychol. (Paris) 110:267–273, 1952b.Google Scholar
  7. Häfliger, R: Chemistry of Tofranil. Can. Psychiatr. Assoc. 4: S69–S74, 1959.Google Scholar
  8. Halpern, B. N.: Experimental research on a series of new chemical substances with powerful antihistaminic activity: The thiodiphenylamine derivatives. J. Allergy 18:263–272, 1947.PubMedCrossRefGoogle Scholar
  9. Hollister, L. E.: Tricyclic antidepressants. N.Engl.J.Med. 299:1106–1109, 1978.PubMedCrossRefGoogle Scholar
  10. Klein, D. F., Gittelman, R., Quitkin, F., and Rifkin, A.: Diagnosis and Drug Treatment of Psychiatric Disorders, 2nd Ed., Williams & Wilkins, Baltimore, 1980.Google Scholar
  11. Klerman, G. L.: Drug therapy of clinical depressions—current status and implications for research on neuropharmacology of the affective disorders. J. Psychiatr. Res. 9:253–270, 1972.PubMedCrossRefGoogle Scholar
  12. Kuhn, R.: Über die Behandlung depressiver Zustände mit einem Imino-dibenzyl-derivat(G 22355). Schweiz. Med.Wochenschr. 35/36:1135–1140, 1957.Google Scholar
  13. Kuhn, R.: The imipramine story, in Discoveries in Biological Psychiatry, F. J. Ayd and B. Blackwell, eds., pp. 205–217, Lippincott, Philadelphia, 1970.Google Scholar
  14. Laborit, H.: Sur l’utilisation de certains agents pharmacodynamiques à action neuro-végétative en période per-et postoperatoire. Acta Chir. Belg. 48:485–492, 1949.Google Scholar
  15. Laborit, H. and Leger, L.: Utilisation d’un antihistaminique de synthèse en thérapeutique pré, per, et post-opératoire. Presse Méd. 58:492, 1950.PubMedGoogle Scholar
  16. Laborit, H., Huguenard, P., and Alluame, R.: Un nouveau stabilisateur vegetatif (le 4560 R. P.). Presse Méd. 60:206–208, 1952.PubMedGoogle Scholar
  17. Lehmann, H.E.: Tricyclic antidepressants: Recollections by H. E.Lehmann, in Discoveries in Pharmacology, vol. 1, M. J. Parnhamand J. Bruinvels, eds., pp. 211–216, Elsevier, Amsterdam, 1983.Google Scholar
  18. Schildkraut, J. J.: The catecholamine hypothesis of affective disorders; a review of supporting evidence. Am. J. Psychiatry 122:509–522, 1965.PubMedGoogle Scholar
  19. Schildkraut, J. J. and Kety, S. S.: Biogenic amines and emotion. Science 156: 21–30, 1967.PubMedCrossRefGoogle Scholar
  20. Schindler, W. and Häfliger, F.: Über Derivate des Iminodibenzyls. Helv. Chim. Acta 37:472–483, 1954.CrossRefGoogle Scholar
  21. Stedman’s Medical Dictionary, 24th Ed., Williams & Wilkins, Baltimore, 1982.Google Scholar
  22. Sulser, F. and Mishra, R.: The discovery of tricyclic antidepressants and their mode of action, inDiscoveries in Pharmacology, vol.1, M.J. Parnham and J. Bruinvels, eds., pp. 233–247, Elsevier, Amsterdam, 1983.Google Scholar
  23. Sulser, F., Vetulani, J., and Mobley, P. L.: Mode of action of antidepressant drugs. Biochem. Pharmacol. 27:257–261, 1978.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Robert A. Maxwell
    • 1
  • Shohreh B. Eckhardt
    • 2
  1. 1.The Wellcome Research Laboratories ResearchTriangle ParkUSA
  2. 2.University of Vermont College of MedicineBurlingtonUSA

Personalised recommendations